VEGF-A is the founding member of the VPF/VEGF family of proteins that also includes VEGFs B, C and D as well as PlGF (placenta growth factor) and a related viral protein, VEGF-E (Dvorak, J Clin Oncol 20:4368-4380, 2002; Am J Pathol 162:1747-1757, 2003; Ferrara et al., Nat Med 9:669-676, 2003; Mukhopadhyay et al., Vascular permeability factor/vascular endothelial growth factor and its receptors: evolving paradigms in vascular biology and cell signaling. In: Aird W (ed) The endothelium: a comprehensive reference. Cambridge University Press, Cambridge, 2007; Bry et al., Circulation 122:1725-1733, 2010; Hagberg et al., Nature 464:917-921, 2010; Shibuya and Claesson-Welsh, Exp Cell Res 312:549-560, 2006; Veikkola and Alitalo, Semin Cancer Biol 9:211-220, 1999). VEGF-A, the subject of this chapter, has critical roles in vasculogenesis and pathological and physiological angiogenesis, acting through receptors (VEGFR- 1, VEGFR-2 and neuropilin) that are expressed on vascular endothelium as well as on certain other cell types (Fig. 1) (Shibuya and Claesson-Welsh, Exp Cell Res 312:549-560, 2006; Veikkola and Alitalo, Semin Cancer Biol 9:211-220, 1999; Bielenberg et al., Exp Cell Res 312:584-593, 2006). The product of a single gene, VEGF-A is alternatively spliced to form several proteins of different lengths, properties and functions. Originally discovered as a potent vascular permeabilizing factor (VPF) (Senger et al., Science 219:983-985, 1983; Dvorak et al., J Immunol 122:166-174, 1979), VEGF-A is also an endothelial cell motogen and mitogen, profoundly alters the pattern of endothelial cell gene expression, and protects endothelial cells from apoptosis (Benjamin et al., J Clin Invest 103:159-165, 1999) and senescence (Dvorak, Am J Pathol 162:1747-1757, 2003). Recently, VEGF-A has been found to have additional critical roles in hematopoiesis and in expansion and differentiation of bone marrow endothelial cell precursors (Seandel et al., Cancer Cell 13:181-183, 2008), in maintenance of the nervous system (Ruiz de Almodovar et al., Physiol Rev 89:607-648, 2009), and in development. Mice lacking even one copy of the VEGF-A gene are embryonic lethal (Ferrara et al., Nat Med 9:669-676, 2003; Carmeliet, Nat Med 9:653-660, 2003). VEGFs C and D are essential for development of the lymphatic system (Veikkola and Alitalo, Semin Cancer Biol 9:211-220, 1999), VEGF-B has a role in the development of coronary arteries and in fatty acid metabolism (Bry et al., Circulation 122:1725-1733, 2010; Hagberg et al., Nature 464:917-921, 2010), and PlGF has important roles in pathological angiogenesis (Carmeliet, Nat Med 9:653-660, 2003; Luttun et al., Nat Med 8:831-840, 2002). VEGF-A also induces abnormal lymphangiogenesis (Nagy et al., J Exp Med 196:1497-1506, 2002).
CITATION STYLE
Dvorak, H. (2017). VEGF A. In Cancer Therapeutic Targets (Vol. 2–2, pp. 625–638). Springer New York. https://doi.org/10.1007/978-1-4419-0717-2_2
Mendeley helps you to discover research relevant for your work.